ReviewHematology/oncology clinics of North America2014
Understanding the biology of melanoma and therapeutic implications.
Review in Hematology/oncology clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 34 citations in OpenAlex.
- Design, Synthesis and Anti-Melanoma Activity of Novel Annexin V Derivative with βInternational journal of molecular sciences · 2023Article
- Intratumoral bacteria in uveal melanoma: A case report.American journal of ophthalmology case reports · 2023Article
- Exosome application in tumorigenesis: diagnosis and treatment of melanoma.Medical oncology (Northwood, London, England) · 2022Review
- Daily Lifestyle and Cutaneous Malignancies.International journal of molecular sciences · 2021Review
- The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma.Cancer medicine · 2021Article
- Article
- MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells.Epigenetics & chromatin · 2019Article
- Targeted Therapy and Immunotherapy for Melanoma in Japan.Current treatment options in oncology · 2019Review
- The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe.Current oncology reports · 2018Review
- AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.Oncogene · 2018Article
- Use of phosphodiesterase type 5 inhibitors and risk of melanoma: a meta-analysis of observational studies.OncoTargets and therapy · 2018Article
- Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.Cancer letters · 2017Review
- Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.Oncotarget · 2017Article
- Resistant mechanisms to BRAF inhibitors in melanoma.Annals of translational medicine · 2016Review
- Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin.PloS one · 2016Article
- Quercetin as an Emerging Anti-Melanoma Agent: A Four-Focus Area Therapeutic Development Strategy.Frontiers in nutrition · 2016Review
- Phenylethanoid Glycosides fromJournal of Cancer · 2016Article
- Spitzoid melanoma of childhood: a case series and review.Melanoma management · 2015Article
- Tenascin-C Signaling in melanoma.Cell adhesion & migration · 2015Review
- Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas.Clinical epigenetics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
From 1976 to 2010, only 2 medications were approved for treating metastatic melanoma. Between 2011 and 2013, 4 agents were approved and other therapies have shown great promise in clinical trials. Fundamental discoveries, such as the identification of oncogenic mutations in most melanomas, the elucidation of the molecular signaling resulting from these mutations, and the revelation that several cell surface molecules serve as regulators of immune activation, have been instrumental in this progress. This article summarizes the molecular pathogenesis of melanoma, describes the current efforts to target oncogene-driven signaling, and presents the rationale for combining immune and molecular targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.